Zealand CEO: Novo Nordisk is "the perfect partner" to market rescue pen

A deal with the Danish pharmaceutical giant is just what Zealand Pharma had hoped for when the company planned to enter licensing deals for its products, says CEO Adam Steensberg.

Adam Steensberg, CEO of Zealand Pharma | Photo: Zealand Pharma

On Wednesday, Zealand Pharma announced that it had entered a licensing and development deal with Novo Nordisk concerning Zegalogue (dasiglucagon), the former firm’s rescue pen against severe hypoglycemia, which is a diabetic emergency caused by low blood sugar.

”It’s completely in line with what we want to achieve, which is to come together with some of the leading firms in the disease areas for which we develop medicines. Novo Nordisk is the leading company within diabetes, so we really couldn’t have got a more perfect partner,” Zealand Pharma CEO Adam Steenberg tells MedWatch.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

FDA fast-tracks Eli Lilly's obesity candidate

Tirzepatide is already approved for type 2 diabetes, and Lilly has been vying for access to the obesity market for a while – the day the drug could be approved in both indications has now been moved up.

Jefferies spots weaknesses in GN

One potential chink in GN’s armor is that the company’s newly announced hearing aid platform, Omnia, isn’t predicted to win significant market shares.

Further reading

Related articles

Latest news

See all jobs